The prognostic importance of tissue polypeptide antigen (TPA) in urine samples of patients with urological cancer5 has been evaluated. TPA concentration correlated well both with the stage of the disease and survival. A simple score system was devised. There was very significant worsening of the prognosis with increasing score.
Introduction
There is a plethora of tumour markers now available which can detect tumours and help in establishing diagnosis and prognosis. These include fetal antigens, enzymes and hormones that are normally produced by the cells in minute quantities, but there is an over-production in the malignant phenotype. To be of clinical value tumour markers need to have a high degree of specificity and sensitivity. Some tumour markers such as carcinoembryonic antigen (CEA) and alphafetoprotein (AFP) have been well studied in clinical situations. Howe, er, the use of a lesser-known substance called tissue polypeptide antigen (TPA) has not been adequately evaluated.
TPA is a polypeptide. It is heterogeneous in nature and SDS-polyacrylamide gel electrophoresis resolves it into molecular weights ranging from between 20 000 and 45 000 daltons. The amino acid sequence of the biologically-active part of TPA is known (Redelius et al. 1980) . The antigenic determinants contain tyrosine and arginine. TPA does not cross-react with CEA, AFP, Tennagen or other known tumour markers (Bjorklund 1983) .
It has been found that sera from apparently healthy male workers exposed to bladder carcinogens contained significantly raised levels of TPA compared with age-matched healthy volunteers (Kumar et al. 1978) . A pilot study of TPA concentration in 24-hour urine samples in patients with urothelial neoplasia gave very promising results (Kumar et al. 1981) .
The present study was carried out to determine whether estimations of TPA concentration in the urine of patients with urological neoplasms have a practical value as an adjunct to the routine clinical methods used in determining prognosis.
Methods
Urine specimens were collected from 172 patients and 21 controls ( Table 1 ). The majority (79%) were over the age of 60 years, with a relatively even age distribution between 61 and 75 years. All persons with a history of systemic disease, urinary tract infections, or non-urological cancers were excluded. At the time of sampling, all cases were carefully assessed by one of the authors (CBC) using the Karnofsky scale. A clinical evaluation, including staging, was carried out within 48 hours of sampling, usually within 3-4 hours of patients going to theatre for endoscopic assessment and/or operations under general anaesthesia. The sampling was always completed before premedication was given. Conventional radiology, ultrasound, radioisotope scans and computerized tomography were also used to stage the disease. Urine cytology was also performed, especially with urothelial tumours, and histological proof was obtained either by biopsy or at the time of operation which was also within hours of collecting specimens. According to the histological grade a TNM (tumour node metastasis) postsurgical classification was made (UICC 1978-82) , thus revising the initial stage if necessary. There were 142 twenty-four hour urine collections and 51 split-urine samples. The spliturine samples covered three time periods, 08.00 to 12.00, 12.00 to 17.00 and 17.00 to 08.00 the following morning, and were respectively called U1, U2 and U3. At the end of each sampling period the volume and pH of urine were recorded. Aliquots (2 ml) of urine were collected in vials, coded and stored frozen at -20°C within one hour of collection. Further aliquots of urine were sent for microculture.
The urinary samples were subsequently tested for TPA levels in batches of 20 using a radioimmunoassay-assay kit Prolifigen (AB Sangtec Bromma, Sweden). The urinary pH was initially adjusted in each sample to 7.3 + 0.2 by the addition of 0.2 mol/l NaOH or HCI. One part of urine (150-200,ul) was mixed with an equal part of dilute phosphate buffered saline containing bovine serum albumin pH 7.3. The basic principle of the assay is the sequential saturation of anti-TPA antibody, first by TPA in the specimen and then by 125I-TPA. The bound radioligand is separated by precipitation with rabbit anti-horse antibody. The radioactivity in the precipitate is measured in a gamma counter. The percentage bound radioligand is calculated from a standard curve. The standard deviations were less than 10% in all samples tested.
Results
The analysis of results was carried out on ordinary and logged data for statistical purposes. There was good correlation between all the urine concentrations of TPA and stage of the disease. The greater the concentration of TPA the higher the stage. The elevation in TPA concentration was non-linear in relation to stage (Figure 1) for both bladder and prostatic cases. There was a similar trend in the relationship between stage of disease and the split urines but it was not statistically significant (data not presented).
Survival curves by TPA concentration in all urine samples are presented in Figure 2 . The survival decreased as the TPA level rose. The relationship between TPA levels and survival with the split urines was not as strong as with the 24-hour urine concentration (data not presented).
A multivariant analysis (Cox) of survival was performed. The variables most significantly related to survival are T Stage (P=0.00001), the initial Karnofsky score (P=0.00006), N Stage (P=0.01500), site of disease (P=0.017) and 24-hour TPA concentration (P=0.0025). Once these five variables are included in the model, no other variable contains any additional information that significantly affects survival. Using this information, a score can be calculated for each patient: The survival graphs of the 193 cases based on prognosis with an increase in score (Figure 3 ). 0 12 24 36 48 MONTHS Figure 3 . Survival related to score: the higher the score, the poorer the prognosis such a model show a definite worsening of Discussion TPA is a cytoplasmic constituent of normal non-epidermal human epithelia and is maintained and increased in carcinomas of these epithelia (Nathrath et al. 1984) . The proliferative activity of these cells increases the release of TPA into the serum. There can be temporary elevation of TPA when infection or trauma is present. These levels are not as high as in patients with established neoplasms and usually return to normal levels much quicker than other parameters, e.g. erythrocyte sedimentation rate.
We have found, as our previous study (Kumar et al. 1981) , that the 24-hour urine concentrations of TPA in urothelial neoplasm are more sensitive than other methods of sampling. 69 This sampling method reflects the production of TPA over a longer time interval rather than random spot (serum) or shorter periods of urinary collection (U1, U2, U3). There are also other advantages with urinary TPA levels. The neoplastic cells do not need to be in contact with urine as TPA is excreted through the kidney. Most of the other available tumour markers are not excreted by the kidneys and when found in urine do so by direct contact of the neoplastic cells with urine. Hence, with TPA noninvasive sampling is possible not only for urothelial tumours but also other urological neoplasms by 24-hour urine concentrations. The TPA concentration in 24-hour urines in this study is important to the model as an adjunct to determining prognosis.
While there are limitations with TPA for site-specificity of neoplasm in the initial diagnosis, this is also true of most other methods of investigation and testing when arriving at a diagnosis initially. However, with the arrival of other noninvasive techniques of siting neoplasms, e.g. computerized tomography, nuclear magnetic resonance and ultrasound, invasive techniques such as cytoscopies and endoscopic biopsies on a repetitive basis should become less frequent.
